Comparative Pharmacology
Head-to-head clinical analysis: LYMEPAK versus TONMYA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYMEPAK versus TONMYA.
LYMEPAK vs TONMYA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lyme disease treatment: Antibiotic combination (amoxicillin/clavulanate) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, disrupting peptidoglycan cross-linking. Clavulanate is a beta-lactamase inhibitor that prevents degradation of amoxicillin by bacterial enzymes.
Topoisomerase II inhibitor; induces DNA double-strand breaks and apoptosis in cancer cells.
100 mg orally twice daily for 18 days, plus 500 mg probenecid orally three times daily for 18 days.
Adults: 500 mg orally twice daily with food.
None Documented
None Documented
Terminal elimination half-life 12-18 hours; prolonged in renal impairment requiring dose adjustment.
Terminal half-life: 12-18 hours (prolonged in renal impairment; dose adjustment required for CrCl <30 mL/min)
Primarily renal (70-80% unchanged), with biliary/fecal elimination accounting for 15-20%.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Category C
Category C
Antibiotic (Tetracycline)
Antibiotic (Tetracycline)